Showing results (181-190 of 208) with videos related to
Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.Journal for Immunotherapy of Cancer|July 31, 2021
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trialVarun Monga, Benjamin J Miller, Munir Tanas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II TrialEzra E W Cohen, Lisle Nabell, Deborah J Wong, et al.Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.Cancers|July 28, 2026
Development of a Cre-Inducible Rabl6a Transgenic Mouse Model That Enhances Sarcoma Growth In VivoEllen M Voigt, Alexandra L Isaacson, Mariah R Leidinger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialGeorge D Demetri, Margaret von Mehren, Robin L Jones, et al.JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)Rana R McKay, Karla V Ballman, Pamela J Atherton, et al.Pageof 21